ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers...
Read moreDetails